Velocity Clinical Research has announced a significant leadership appointment with Dr. Ronnie Beboso joining as UK Medical Director. This strategic move comes as the organization continues to expand its clinical operations throughout the United Kingdom and across Europe, reinforcing its commitment to medical excellence.
Extensive Experience in Clinical Research
Dr. Beboso brings two decades of comprehensive clinical research experience to his new position, having worked on more than 70 studies spanning early-phase through late-phase development. His background includes extensive work as both Principal Investigator and Chief Investigator across numerous therapeutic areas, providing him with deep insight into the complete clinical trial lifecycle.
Strategic Leadership Responsibilities
In his role as UK Medical Director, Dr. Beboso will oversee all UK physicians within the Velocity network while providing strategic medical leadership. He will play a crucial role in evolving Velocity's medical model to meet the demands of a growing pan-European organization, ensuring that clinical excellence remains central to the company's expansion.
Dr. Sarah Smiley, Velocity Chief Physician Officer, emphasized the importance of this appointment, stating: "As Velocity continues to establish and consolidate its European presence, maintaining strong medical leadership alongside our commercial and operational capabilities is essential. Ronnie brings credibility, depth, and a true medical perspective to our leadership team."
Distinguished Career Background
Dr. Beboso is a UK-registered physician with formal training in general surgery and a license to practice. His distinguished career includes senior research physician roles at several prominent organizations:
- IQVIA and Chiltern, where he focused on first-in-human and early-phase studies
- Medinova and Accellacare Clinical Research, where he conducted Phase II-IV clinical trials
Most recently at Accellacare, he served as Senior Clinical Research Physician, providing medical oversight across multiple sites while managing doctors and acting as medical lead for dermatology, respiratory, and pain studies. His expertise extends to numerous therapeutic areas including cardiology, endocrinology, gastroenterology, women's health, and metabolic disease.
Combining Clinical Work with Leadership
Dr. Beboso expressed enthusiasm for his new position, noting: "Clinical trials allow physicians to help patients today while advancing treatments that will benefit patients tomorrow. What drew me to Velocity is the opportunity to combine hands-on clinical work with broader medical leadership, supporting physicians, spending meaningful time with patients, and contributing to the development of new medicines that can genuinely change lives."
At Velocity, Dr. Beboso will continue to serve as Principal Investigator on selected studies while focusing on mentoring and developing the next generation of investigators across the UK. A core part of his responsibilities will involve supporting physician career progression, expanding therapeutic capabilities, and ensuring clinical excellence remains central as Velocity continues its growth trajectory.
The appointment represents a significant strengthening of Velocity's medical leadership as the organization scales its European operations, positioning the company to maintain its commitment to scientific rigor and patient-centered research while expanding its geographic footprint.
